PYOTT DAVID E I sold $1.1M of ALNY

Alnylam will present five-year data from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) at AHA and ISA 2026, showing long-term benefits in treating transthyretin amyloidosis (ATTR). The study includes open-label extension data and post hoc analyses demonstrating preserved exercise capacity and cardiopulmonary performance. Additional real-world evidence and comparisons with other treatments will also be presented.

AstraZeneca (AZN) reiterated its $80B revenue target by 2030, announced a $1.5B cost-savings program, and shares rose 7%. Alnylam (ALNY) reported $1.13B Amvuttra revenue, but shares fell 20% due to concerns over Medicare reimbursement and insurer policies. Regeneron (REGN) saw shares rise 13% after reporting record sales for Dupixent, Eylea, and Libtayo, beating expectations.

Bernstein downgraded Alnylam Pharmaceuticals to Market Perform, lowering its price target to $199 from $376. The new target suggests a 14.4% upside from the Oct 29 close of $174. Recent analyst price targets for the company range from $220 to $320.

Alnylam Pharmaceuticals (ALNY) stock dropped 25.1% on October 29, 2026, despite beating Q3 revenue estimates. Management expressed dissatisfaction with demand growth, lowering TTR product sales guidance. Product revenue grew 52% YoY, led by AMVUTTRA. The stock's decline was independent of sector and market trends.

Raymond James downgraded Alnylam Pharmaceuticals (ALNY) to Outperform from Strong Buy, lowering its price target to $315 from $420. The move follows Alnylam's Q3 2026 results, citing uncertainty around Amvuttra's near-term trends. The stock has dropped 22% in a week, trading near its 52-week low. Despite beating earnings estimates, concerns about softer guidance and commercial delays led to the downgrade. Stifel also downgraded ALNY to Hold, reducing its price target to $225.

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 earnings, highlighting a 59% surge in TTR franchise but noting challenges. AMVUTRA demand growth lagged, and Q4 headwinds are expected due to inventory, pricing, and 340B rule uncertainty. The company delayed 2027 guidance. Management discussed strategies to address demand growth hurdles and potential 340B impacts. Key events, including data releases and clinical development updates, were outlined.